Medicare Enrolled
Dr. Mark Goldstein, MD
Rheumatology · Staten Island, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Goldstein from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Goldstein?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Goldstein
Dr. Mark Goldstein is a rheumatology specialist in Staten Island, NY, with 21 years of NPI registration. Based on federal Medicare data, Dr. Goldstein performed 76,983 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Goldstein received a total of $35,790 from 44 pharmaceutical and/or device companies across 1298 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Goldstein is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years of NPI registration
▲ Top 6% volume in NY
$35,790 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗76,983
Medicare services
Top 6% in NY for rheumatology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
51,640 | $4 | $11 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
7,826 | $34 | $70 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
7,250 | $11 | $50 |
| Denosumab injection (Prolia/Xgeva) | 5,700 | $18 | $32 |
| Hymovis intra-articular injection An injection of Hymovis, a hyaluronan derivative, administered directly into a joint space. |
2,233 | $13 | $36 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
693 | $72 | $125 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
353 | $68 | $250 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
273 | $126 | $584 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
272 | $1 | $30 |
| Injection, methylprednisolone acetate, 40 mg | 140 | $6 | $38 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
135 | $74 | $194 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
122 | $27 | $150 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
111 | $47 | $85 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
99 | $4 | $38 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
55 | $99 | $175 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
43 | $136 | $360 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
38 | $35 | $120 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
20.3% high complexity
78.5% medium
1.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$35,790
Total received (2018-2024)
Avg $5,113/year across 7 years
Top 14% in NY for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
44
Companies
1,298
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,001
2023
$3,933
2022
$3,930
2021
$2,580
2020
$1,610
2019
$3,838
2018
$15,897
Payments by company (2024)
ABBVIE INC.
$1,267
Amgen Inc.
$432
UCB, Inc.
$322
Janssen Biotech, Inc.
$267
PFIZER INC.
$245
AstraZeneca Pharmaceuticals LP
$227
Radius Health, Inc.
$204
Novartis Pharmaceuticals Corporation
$182
Lilly USA, LLC
$181
Boehringer Ingelheim Pharmaceuticals, Inc.
$154
GENZYME CORPORATION
$105
Aurinia Pharma U.S., Inc.
$95
Genentech USA, Inc.
$73
E.R. Squibb & Sons, L.L.C.
$70
GlaxoSmithKline, LLC.
$53
Fresenius Kabi USA, LLC
$37
Fidia Pharma USA Inc.
$29
ANI Pharmaceuticals, Inc.
$21
Mallinckrodt Hospital Products Inc.
$21
SCILEX PHARMACEUTICALS INC.
$17
Top 3 companies account for 50.5% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Pharma plc
$8,646
PFIZER INC.
$6,047
ABBVIE INC.
$3,625
Amgen Inc.
$3,158
Janssen Biotech, Inc.
$1,943
Novartis Pharmaceuticals Corporation
$1,180
AbbVie Inc.
$1,123
AstraZeneca Pharmaceuticals LP
$989
E.R. Squibb & Sons, L.L.C.
$837
AbbVie, Inc.
$830
UCB, Inc.
$810
Lilly USA, LLC
$806
GlaxoSmithKline, LLC.
$738
Aurinia Pharma U.S., Inc.
$574
Genentech USA, Inc.
$570
Horizon Therapeutics plc
$548
Celgene Corporation
$422
Regeneron Healthcare Solutions, Inc.
$350
Radius Health, Inc.
$326
Antares Pharma, Inc.
$260
Boehringer Ingelheim Pharmaceuticals, Inc.
$246
Mallinckrodt Enterprises LLC
$212
Mallinckrodt Hospital Products Inc.
$194
GENZYME CORPORATION
$192
FIDIA PHARMA USA INC.
$183
Flexion Therapeutics, Inc.
$178
Hikma Pharmaceuticals USA
$177
Fidia Pharma USA Inc.
$119
Fresenius Kabi USA, LLC
$90
Daiichi Sankyo Inc.
$77
Takeda Pharmaceuticals U.S.A., Inc.
$45
Sebela Pharmaceuticals Inc.
$42
West-Ward Pharmaceuticals
$37
Mallinckrodt LLC
$31
Sobi, Inc
$31
Bioventus LLC
$22
ANI Pharmaceuticals, Inc.
$21
SCILEX PHARMACEUTICALS INC.
$17
MEDAC PHARMA, INC.
$17
Kaleo, Inc.
$16
Ferring Pharmaceuticals Inc.
$16
Endo Pharmaceuticals Inc.
$15
MEDEXUS PHARMA, INC.
$13
SANOFI-AVENTIS U.S. LLC
$12
Top 3 companies account for 51.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · BOSULIF · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Durolane · EUFLEXXA · EVENITY · Enbrel · Evzio · FORTEO · GLOPERBA · HUMIRA · HYALGAN · HYMOVIS · Humira · Hymovis · IDACIO · ILARIS · KEVZARA · KEVZARA SARILUMAB INJECTION · KRYSTEXXA · Kineret · Kloxxado · LUPKYNIS · LYRICA · Mitigare · Morphabond ER · Movantik · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ORENCIA · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SPEVIGO · STELARA · SYNVISC-ONE · TALTZ · TAVNEOS · TREMFYA · Tavneos · Trintellix · Tymlos · Uloric · XELJANZ · XENPOZYME · XIAFLEX · XYOSTED · Zilretta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Rheumatologists in nearby ZIP areas
383
County median income
$98,290
Nearest hospital to ZIP centroid (approximate)
RICHMOND UNIVERSITY MEDICAL CENTER
1.2 mi
1.2 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Goldstein is a mixed practice specialist, with above-average Medicare volume (top 6% in NY), with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Goldstein experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Goldstein performed 51,640 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Goldstein receive payments from pharmaceutical companies?
Yes. Dr. Goldstein received a total of $35,790 from 44 companies across 1,298 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Goldstein's costs compare to other rheumatologists in Staten Island?
Dr. Goldstein's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Goldstein) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Staten Island
Browse rheumatologists in Staten Island ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in NY
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in NY
Which NY rheumatologists receive the most from drug and device companies.
By company
Horizon Pharma plc Payments to Doctors
See all physicians who received payments from Horizon Pharma plc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology